<DOC>
	<DOCNO>NCT01550705</DOCNO>
	<brief_summary>In erythropoietic protoporphyria accumulation protoporphyrin IX ( PPIX ) plasma liver . The reason build either last step make heme , insertion iron PPIX , rate limiting increase activity first step heme pathway . It may possible decrease amount PPIX make see decrease symptom . The first step make heme key step pathway use vitamin B6 cofactor . If investigator limit amount vitamin B6 investigator possibly reduce activity rate limit step . With decreased activity enzyme may possible body utilize PPIX make none build .</brief_summary>
	<brief_title>Effect Isoniazid Protoporphyrin Levels Erythropoietic Protoporphyria</brief_title>
	<detailed_description>Clinically , erythropoietic protoporphyria ( EPP ) X-linked EPP ( XLEPP ) characterize painful , non-blistering cutaneous photosensitivity onset early childhood . EPP common porphyria child third common adult ( porphyria cutanea tarda acute intermittent porphyria ) . Reports prevalence vary 5 15 case per million population . EPP due case decrease activity ferrochelatase ( FECH ) , enzyme catalyzes incorporation ferrous iron PPIX , final step production heme . The pattern inheritance autosomal recessive . However , homozygosity FECH mutation rare . Rather , decrease activity consequence combination inherit inactivating mutation affect one FECH allele intronic polymorphism alters splice allele . The alternative splice site , use , produce non-functional FECH messenger ribonucleic acid ( mRNA ) . The alternative splice site use approximately 40 % time . Therefore , polymorphic allele produce approximately 60 % normal FECH activity , reason , term hypomorphic . When hypomorphic FECH allele trans non-functional mutant allele result 30 % less normal FECH enzyme activity . This subnormal FECH activity become rate-limiting , result accumulation intracellular PPIX . Although defect presumably express tissue , PPIX responsible photosensitivity derive primarily marrow reticulocyte . Aminolevulinic acid synthase ( ALAS ) , first , rate-limiting enzyme heme biosynthetic pathway , catalyze condensation glycine succinyl-Coenzyme A ( succinyl-CoA ) form aminolevulinic acid ( ALA ) , require pyridoxal 5'-phosphate cofactor . ALAS mammalian cell localize mitochondrial matrix . The enzyme synthesize precursor protein cytosol transport mitochondrion . Two separate ALA synthase gene encode housekeep ( tissue-nonspecific ) erythroid specific form enzyme ( ALAS1 ALAS2 , respectively ) . The gene human ALAS1 3p.21 locus ALAS2 X-chromosome , Xp11.2 . The two form ALAS differentially regulate , ALAS1 housekeep gene express cell ALAS2 driven erythroid specific transcription factor GATA1 NF-E2 . Additionally , ALAS2 mRNA contain iron-responsive element ( IRE ) 5'-untranslated region , similar mRNAs encode ferritin transferrin receptor ( IRE gene 's 3 ' UTR ) . Gel retardation analysis show iron-responsive element ALAS2 mRNA functional [ evidence bind iron regulator protein 2 ( IRP2 ) ] , indicate translation erythroid-specific mRNA directly link availability iron heme erythroid cell . In case , intracellular iron concentration relatively high , available binding IRP2 , process enhances ubiquitin-mediated degradation IRP2 . Under condition , IRP2 unavailable binding IRE element ALAS2 , clear message efficient translation . Conversely , intracellular iron relatively low , IRP2 degradation restrict , make protein available binding IRE thereby block translation ALAS2 mRNA . Recently , variant form EPP , inherit X-linked pattern ( XLEPP ) , show due ALAS2 gain-of-function mutation exon 11 . The mutation result truncate form protein supranormal specific activity result less constrained enzyme-substrate interaction , result overproduction PPIX . This situation contrast EPP mutate FECH PPIX accumulate deficient heme formation . ALAS1 2 use pyridoxal phosphate ( PLP ) cofactor . PLP modify form vitamin B6 . It show PLP complex isoniazid deplete cofactor . This PLP depletion one cause sideroblastic anemia . The investigator test hypothesis depletion PLP lead decrease activity ALAS .</detailed_description>
	<mesh_term>Protoporphyria , Erythropoietic</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Protoporphyrin IX</mesh_term>
	<criteria>All subject enrol Longitudinal Study Porphyrias . In patient EPP inclusion criterion base 1. clinical feature 2. biochemical finding , document laboratory report porphyriaspecific test perform 1980 3. molecular finding document identification mutation FECH ALAS2 gene ( molecular evidence EPP require inclusion study ) . These data obtain Porphyria Rare Disease Clinical Research Consortium Longitudinal Study ( RDCRN Protocol 7201 ) . An individual must willing give write informed consent 18 year age great . Autosomal EPP ( EPP ) Xlinked protoporphyria ( XLEPP ) Clinical feature b require A history nonblistering cutaneous photosensitivity , usually early age onset . A diagnosis EPP XLEPP relative . Biochemical finding A marked increase erythrocyte protoporphyrin [ total erythrocyte protoporphyrin &gt; 200 ug/dL , 1.5fold increase relative upper limit normal 80 ug/dL , predominance free protoporphyrin ( 85100 % EPP 5085 % XLEPP ) . Note : Methods laboratory measure free erythrocyte protoporphyrin ( FEP ) actually measure zinc protoporphyrin , result rely upon diagnosis characterize phenotype EPP XLEPP . Increased plasma porphyrin fluorescence emission peak ~634 nm . Normal urinary porphyrin ( except patient hepatobiliary impairment ) , normal ALA porphobilinogen ( PBG ) . Molecular finding one following : A disease cause FECH mutation trans IVS348C &gt; T low expression FECH allele ( aEPP ) Two diseasecausing FECH mutation ( EPP , recessive variant ) A gainoffunction ALAS2 Cterminal deletion/exon 11 mutation ( XLEPP ) Patients diagnosis EPP document DNA test . Patients evidence active liver injury define serum transaminase concentration great three time upper limit normal , history recent ( within 3 month enrollment ) ongoing alcohol abuse , diabetes mellitus require therapy , renal insufficiency ( serum creatinine &gt; 2.0 mg/ml ) evidence malnutrition ( base subnormal plasma concentration transthyretin ) ineligible participation study . Pregnant and/or lactate woman exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Protoporphyria</keyword>
	<keyword>Porphyria</keyword>
	<keyword>Porphyrins</keyword>
</DOC>